The Synthetic Routes of (3R,3aS,4S,4aS,7R,9aR)-1,3,3a,4,4a,5,6,7,8,9a-Decahydro-3-methyl-7-nitro-1-oxo-N,N-diphenylnaphtho[2,3-c]furan-4-carboxamide

(3R,3aS,4S,4aS,7R,9aR)-1,3,3a,4,4a,5,6,7,8,9a-Decahydro-3-methyl-7-nitro-1-oxo-N,N-diphenylnaphtho[2,3-c]furan-4-carboxamide, also known as MK-801, is a synthetic compound that has been widely studied in the field of medicinal chemistry.
It was first synthesized in 1987 by Merck & Co.
and has since been evaluated for its potential therapeutic uses in various diseases, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The synthesis of MK-801 involves several steps and can be achieved through several synthetic routes.
One of the most common methods of synthesizing MK-801 is through a four-step synthesis route that involves the synthesis of a key intermediate, (2-chloro-5-nitrophenyl)methanol, followed by a series of chemical reactions to form the final product.

Step 1: Synthesis of 2-chloro-5-nitrophenyl)methanol

The synthesis of 2-chloro-5-nitrophenyl)methanol begins with the synthesis of 2-chloro-5-nitroanisole, which is then treated with methanol in the presence of a catalyst, such as sodium hydroxide, to form the desired product.

Step 2: Nitration of N-methylphenylacetamide

Next, N-methylphenylacetamide is treated with nitric acid to form N-methyl-3-nitrophenylacetamide.

Step 3: Dehydration of N-methyl-3-nitrophenylacetamide

N-methyl-3-nitrophenylacetamide is then treated with sodium hydride and DMF to dehydrate the compound, forming N-methyl-3-nitrophenylacetamide.

Step 4: Amination of N-methyl-3-nitrophenylacetamide

Finally, N-methyl-3-nitrophenylacetamide is treated with ammonia and triethylamine to form the final product, (2-chloro-5-nitrophenyl)methanol.

Once the desired intermediate is synthesized, the final synthesis steps involve the treatment of (2-chloro-5-nitrophenyl)methanol with various reagents to form the final product, (3R,3aS,4S,4aS,7R,9aR)-1,3,3a,4,4a,5,6,7,8,9a-Decahydro-3-methyl-7-nitro-1-oxo-N,N-diphenylnaphtho[2,3-c]furan-4-carboxamide.

Applications and Potential Therapeutic Uses

MK-801 has been extensively studied for its potential therapeutic uses in various diseases, including Alzheimer's disease, Parkinson's disease, and schizophrenia.
It has been found to have potent affinity for 5-HT2A receptors, which are believed to play a role in the modulation of dopamine release in the brain.
This property has led to its use as a research tool in the study of neurotransmitter release and receptor function.

However, due to its potential to cause adverse effects, such as halluc